Filing identity and reporting period
The supplied filing is Galena Biopharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed March 17, 2014. This does not match the request metadata naming SELLAS Life Sciences Group, Inc. The filing reports annual results, with unaudited fourth-quarter figures also included.
Business context
Galena was a biopharmaceutical company developing oncology products and had recently begun commercial sales of Abstral, a fentanyl sublingual tablet for breakthrough cancer pain. Its pipeline included NeuVax, in a pivotal Phase 3 breast-cancer study; GALE-301, in early-stage ovarian and endometrial cancer trials; and GALE-401, acquired in January 2014 for development in essential thrombocythemia.
Financial results and position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Net revenue | $2.487 million | None |
| Operating loss | $33.840 million | $21.199 million |
| Net loss | $76.678 million | $34.969 million |
| Net loss per share | $0.85 | $0.56 |
| Cash used in operating activities | $28.908 million | $20.963 million |
| Cash and cash equivalents at year-end | $47.787 million | $32.807 million |
| Total debt at year-end | $9.892 million | None |
FY 2013 gross profit was approximately $1.836 million, or about 74% of revenue, after cost of revenue and acquired-intangible amortization. Revenue came from Abstral, launched in the fourth quarter. Fourth-quarter revenue was $1.317 million and net loss was $48.501 million.
Net loss increased substantially, principally because the company recorded a $44.001 million non-cash increase in the fair value of liability-classified warrants, driven in part by the rising share price. Research and development expense rose 44% to $21.076 million, mainly from the NeuVax Phase 3 trial; selling, general and administrative expense rose 122% to $14.600 million, mainly from building the Abstral sales and marketing organization. The balance sheet included $53.455 million of current assets and $62.447 million of current liabilities; the latter included $48.965 million in warrant liabilities. Stockholders’ equity was $5.886 million.
Cash increased during 2013 with $37.5 million of net proceeds from a public offering, $9.9 million from debt financing, and other financing proceeds. The company also spent approximately $15.1 million acquiring Abstral rights. Management said cash, together with expected Abstral revenue, should fund operations for the foreseeable future, while cautioning that this depended on plans and revenue expectations. A further $5 million debt tranche was available only if conditions were met.
Outlook, risks, and unusual items
- Management expected 2014 Abstral net revenue of approximately $11 million to $15 million; this was a forecast, not a reported result.
- Management expected continued operating losses while commercializing Abstral and advancing clinical programs. Profitability was not assured.
- Key risks include Abstral market uptake, reimbursement and pricing, generic and branded competition, controlled-substance regulation and supply quotas, and reliance on contract manufacturers and other service providers.
- NeuVax and other candidates remained subject to clinical, regulatory, manufacturing, funding, and intellectual-property risks. The FDA Special Protocol Assessment for NeuVax did not guarantee approval.
- In February and March 2014, the company disclosed two shareholder derivative suits, three securities class actions, and an SEC investigation concerning matters involving the company and an investor-relations firm. The company said it was cooperating with the SEC and intended to defend the suits; potential losses could not be estimated.
- After year-end, the company acquired GALE-401 and partnered with Dr. Reddy’s for NeuVax development and commercialization in India. It also reported substantial warrant and option exercises through March 14, 2014, generating cash proceeds but issuing additional shares.
- The auditor gave an unqualified opinion on the 2013 financial statements and concluded internal control over financial reporting was effective. Management also reported effective disclosure controls.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing names Galena Biopharma, Inc., not SELLAS Life Sciences Group, Inc.
- Track Abstral sales, gross-to-net adjustments, reimbursement access, and performance against the 2014 revenue forecast.
- Assess the cash runway against operating cash burn, clinical spending, debt service, and the conditions for accessing the additional debt tranche.
- Review the warrant-liability accounting and potential dilution from outstanding warrants, options, and milestone-based share payments.
- Follow NeuVax trial progress, GALE-301 and GALE-401 development, and the status and potential consequences of the lawsuits and SEC investigation.